TICKERNERD
Menu
GNLXGNLXHealthcare · Biotechnology

GNLX Stock Forecast: Genelux Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.49
+0.40% on the day

The 5 Wall Street analysts covering Genelux Corp. hold a median 12-month price target of $16 — +542.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$112.7M
Ticker Nerd rank
22 / 100
Median analyst target
$16
Analysts covering
5
Revenue$0.0
Operating income−$9.6M
Net income−$9.5M
Free cash flow−$8.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.2%
1M
−6.0%
YTD
−42.9%
1Y
−31.8%
From 52W high
−69.8%
From 52W low
+8.3%
$2.30
$8.24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GNLX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Genelux Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
22 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
75
Size
74
Revisions
47
Volatility
47
Growth
29
Value
27
Quality
19
Momentum
17
Issuance
16

Accruals (75): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GNLX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GNLX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00$35.00Oct 25Jan 26Apr 26Jul 26GNLXHigh $31Median $16Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $12Median $16High $31

The green dot is the last close — the median target sits +542.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Mar 2026BenchmarkMaintainsSpeculative Buy$23 → $20
21 Oct 2025Lake StreetInitiatesBuy—
21 July 2025LUCID CAPITAL MARKETSInitiatesBuy—
8 May 2025BenchmarkMaintainsSpeculative Buy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.MaintainsBuy—
29 Oct 2024GuggenheimInitiatesBuy—
27 Aug 2024Roth MKMInitiatesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
3 June 2024BenchmarkReiteratesSpeculative Buy—
31 May 2024BenchmarkMaintainsSpeculative Buy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
3 Apr 2024BenchmarkReiteratesSpeculative Buy—
2 Apr 2024HC Wainwright & Co.MaintainsBuy—
27 Nov 2023HC Wainwright & Co.InitiatesBuy—
24 Nov 2023BenchmarkMaintainsSpeculative Buy—
12 Sept 2023Maxim GroupInitiatesBuy—
9 June 2023BenchmarkMaintainsSpeculative Buy—
18 May 2023Brookline CapitalInitiatesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GNLX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GNLX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Genelux Corp. returned −31.8% against +17.5% for the S&P 500, dividends included.

GNLX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26GNLXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GNLX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Genelux Corp. (GNLX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
14082.6×

Cheaper than 1% of US stocks

Price / book
6.9×

Cheaper than 14% of US stocks

EV / EBITDA
−2.6×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−455275.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−177.9%

Higher than 8% of US stocks

Return on assets
−77.9%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Genelux Corp. (GNLX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Genelux Corp. has a market value of $112.7M and an enterprise value of $95.3M.

  • Revenue in the twelve months to 30 June 2026: $8K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$35.6M, a −444950.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$28.7M.

  • Shares outstanding: 45.1M.

  • Trailing P/E: −2.9×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Genelux Corp. employs 25 people — $320.0 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

GNLX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GNLXGenelux Corp.$112.7M
22
AARDAardvark Therapeutics, Inc.$111.7M
17
SEERSeer, Inc. (California)$109.7M
72
BDTXBlack Diamond Therapeutics, Inc.$113.5M
57
VANIVivani Medical, Inc.$114.6M
39
RANIRani Therapeutics Holdings, Inc.$114.9M
62
ENGNenGene Therapeutics, Inc.$116.2M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Genelux Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GNLX news & analysis

Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy

GlobeNewsWire · 9 Sept 2026positive

Genelux announced the publication of a case in which a platinum-relapsed small cell lung cancer patient achieved 16.7 months of progression-free survival and an 84.6% reduction in target lesion size following systemically delivered Olvi-Vec-primed immunochemotherapy with platinum rechallenge. Both outcomes exceeded those achieved in the patient's prior platinum-based first-line therapy.

Why it matters — The published case provides clinical data supporting Olvi-Vec's potential efficacy in a challenging platinum-relapsed SCLC setting.

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

GlobeNewsWire · 13 Aug 2026neutral

Genelux Corporation reported its second quarter financial results and provided business updates. The company stated that topline data from the Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec is expected in the second half of 2026, and additional dose-escalation updates for Olvi-Vec systemic development programs are anticipated in 2026.

Why it matters — Genelux watchers would track these announced timelines for Olvi-Vec's pivotal ovarian cancer trial data and systemic program updates as key near-term milestones for the company's pipeline.

FAQ

Frequently asked questions about GNLX stock

What is the GNLX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Genelux Corp. have a median 12-month price target of $16, with estimates ranging from $12 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GNLX stock a buy right now?

Of the 5 analysts covering Genelux Corp., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Genelux Corp. 22 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GNLX?

As at 12 Sept 2026, Genelux Corp. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (75 of 100).

Will GNLX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +542.6% from the last close, and Ticker Nerd's factor model ranks Genelux Corp. 22 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GNLX stock forecast for 2030?

No analyst covering Genelux Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GNLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $31 over the next 12 months.

How has GNLX stock performed over the past year?

Genelux Corp. returned -31.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Genelux Corp. do?

Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. Its lead program, Olvi-Vec, is a modified vaccinia virus-based candidate designed to selectively target cancer cells while stimulating an anti-tumor immune response.

What is the latest news on GNLX?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy". Genelux announced the publication of a case in which a platinum-relapsed small cell lung cancer patient achieved 16.7 months of progression-free survival and an 84.6% reduction in target lesion size following systemically delivered Olvi-Vec-primed immunochemotherapy with platinum rechallenge. Both outcomes exceeded those achieved in the patient's prior platinum-based first-line therapy.

Company

About Genelux Corp.

Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. Its lead program, Olvi-Vec, is a modified vaccinia virus-based candidate designed to selectively target cancer cells while stimulating an anti-tumor immune response. The company also advances CHOICE, a discovery and development platform, alongside a broader pipeline of engineered virus-based product candidates. Genelux serves the oncology market through drug research, development, and clinical trial services centered on immuno-oncology applications. Headquartered in Westlake Village, California, Genelux Corporation concentrates on current therapeutic programs and specialty biotechnology solutions aimed at addressing unmet needs in cancer treatment.

CEO Mr. Thomas D. Zindrick J.D. · 25 employees · United States · https://www.genelux.com